SCHEMBL21592281

SCHEMBL21592281

O=c1c(CN(CCCc2cncc3ccccc23)Cc2ccncc2)coc2c1ccc1ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.39
▸ POLB P06746 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ PTPN1 P18031 1/20 0.39
▸ CYP11B1 P15538 3/20 0.38
▸ CYP11B2 P19099 3/20 0.38
▸ CYP17A1 P05093 2/20 0.38
▸ CYP19A1 P11511 2/20 0.38
▸ ALDH1A1 P00352 4/20 0.35
▸ MAPT P10636 3/20 0.35
▸ GAA P10253 2/20 0.35
▸ KDM4E B2RXH2 2/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ CYP1A2 P05177 3/20 0.34
▸ CYP1A1 P04798 2/20 0.34
▸ CYP1B1 Q16678 2/20 0.34
▸ CFTR P13569 1/20 0.34
▸ KCNA5 P22460 2/20 0.32
▸ PDE10A Q9Y233 1/20 0.32
▸ HPGD P15428 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21591432 0.87 KCNA5 (0.42) KMT2APOLBMEN1PTPN1CYP11B1
SCHEMBL21591442 0.83 KMT2A (0.35) KMT2APOLBMEN1PTPN1CYP11B1
SCHEMBL21592278 0.81 POLB (0.38) KMT2APOLBMEN1PTPN1CYP11B1
SCHEMBL21591444 0.80 CYP11B1 (0.42) KMT2APOLBMEN1PTPN1CYP11B1
SCHEMBL21592291 0.78 KMT2A (0.35) KMT2APOLBMEN1PTPN1CYP11B1
SCHEMBL21592285 0.77 KCNA5 (0.36) KMT2APOLBMEN1PTPN1CYP11B1
SCHEMBL21592250 0.75 KCNA5 (0.44) POLBCYP11B1CYP11B2ALDH1A1MAPT
SCHEMBL21591440 0.75 CYP11B1 (0.60) PTPN1CYP11B1CYP11B2CYP17A1CYP19A1
SCHEMBL21591506 0.73 HDAC3 (0.40) CYP11B1CYP11B2CYP17A1CYP19A1ALDH1A1
SCHEMBL21591463 0.72 CYP11B1 (0.54) CYP11B1CYP11B2CYP17A1CYP19A1KCNA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12162863-B2 Modulators of stimulator of interferon genes (STING) Ryvu Therapeutics S.A. (PL) 2024-12-10 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2022-12-22 — — US disclosed
WO-2019238786-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2019-12-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12162863-B2 Modulators of stimulator of interferon genes (STING) STING1, IRF3, CGAS KMT2A 4721/4885POLB 292/4885MEN1 2184/4885
US-20220402898-A1 MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS KMT2A 4721/4885POLB 292/4885MEN1 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback